Results 171 to 180 of about 316,592 (249)

Novel volumetric modulated arc therapy approach for lattice radiation therapy for bulky liver tumors. [PDF]

Front Oncol
Chung CV, Nair SS, Khan MS, Nguyen CI, Martin-Paulpeter RM, Ludmir EB, Court LE, Niedzielski JS.   +7 more
europepmc   +1 more source

Electrochemical Analysis of cobalt hydroxide layered carbon spheres synthesized via hydrothermal route

, 2019
P. Devendran
openalex   +1 more source

Free paths and transport phenomena gases and the quantum theory of collisions. I.—The rigid sphere model [PDF]

, 1933
H. S. W. Massey, C. B. O. Mohr
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Immunocytokines in cancer immunotherapy: opportunities and challenges. [PDF]

Front Oncol
Wang S, Yao L, Cai J, Gao H, Zhou F.
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Efficient cation separation based on humidity control and adsorption. [PDF]

Nat Commun
Liang J, Chen X, Li C, Zhang Y, Feng J, Wu C, Yang Y, Xue N, Zhang X, Yang Y, Gao T, Wei R, Yu J, Hu X, Zhang Y, Yu Y, Liu W.   +16 more
europepmc   +1 more source

Anomalous Chained Turbulence in Actively Driven Flows on Spheres [PDF]

, 2018
Oscar Mickelin, Jonasz Słomka, Keaton J. Burns, Daniel Lecoanet, Geoffrey M. Vasil, Luiz M. Faria, Jörn Dunkel   +6 more
openalex   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source